Table of Contents Author Guidelines Submit a Manuscript
Journal of Analytical Methods in Chemistry
Volume 2013, Article ID 179627, 10 pages
http://dx.doi.org/10.1155/2013/179627
Research Article

Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma

Department of Analytical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, 34093 Istanbul, Turkey

Received 28 December 2012; Accepted 19 February 2013

Academic Editor: Sibel A. Ozkan

Copyright © 2013 Serife Evrim Kepekci Tekkeli. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, “Global burden of hypertension: analysis of worldwide data,” The Lancet, vol. 365, no. 9455, pp. 217–223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. S. E. Kjeldsen, K. A. Jamerson, G. L. Bakris et al., “Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study,” Blood Pressure, vol. 17, no. 1, pp. 7–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. K. A. Jamerson, G. L. Bakris, B. Dahlö et al., “Exceptional early blood pressure control rates: the ACCOMPLISH trial,” Blood Pressure, vol. 16, no. 2, pp. 80–86, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. W. B. White, T. Giles, G. L. Bakris, J. M. Neutel, G. Davidai, and M. A. Weber, “Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting,” American Heart Journal, vol. 151, no. 1, pp. 176–184, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Budavari, The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals, Whitehouse Station, NJ, USA, Merck and Co., 13th edition, 2001.
  6. S. E. Kjeldsen, H. R. Brunner, G. T. McInnes, and P. Stolt, “Valsartan in the treatment of hypertension,” Aging Health, vol. 1, pp. 27–36, 2005. View at Google Scholar
  7. British Pharmacopoeia, vol. 1, Her Majesty's Stationary Office, London, UK, 2008.
  8. K. H. Rahn, “Clinical pharmacology of diuretics,” Clinical and Experimental Hypertension, vol. 5, no. 2, pp. 157–166, 1983. View at Google Scholar
  9. R. B. Patel, U. R. Patel, M. C. Rogge et al., “Bioavailability of hydrochlorothiazide from tablets and suspensions,” Journal of Pharmaceutical Sciences, vol. 73, no. 3, pp. 359–361, 1984. View at Publisher · View at Google Scholar
  10. K. Wellington and D. M. Faulds, “Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension,” Drugs, vol. 62, no. 13, pp. 1983–2005, 2002. View at Google Scholar · View at Scopus
  11. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. W. C. Cushman, C. E. Ford, J. A. Cutler et al., “Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attact trial (ALLHAT),” Journal of Clinical Hypertension, vol. 4, no. 6, pp. 393–404, 2002. View at Google Scholar
  13. K. Jamerson, M. A. Weber, G. L. Bakris et al., “Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients,” New England Journal of Medicine, vol. 359, no. 23, pp. 2417–2428, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. V. Milani, “Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy,” American Journal of Managed Care, vol. 11, no. 7, pp. S220–S227, 2005. View at Google Scholar · View at Scopus
  15. C. J. Pepine, E. M. Handberg, R. M. Cooper-DeHoff et al., “A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 21, pp. 2805–2816, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Oparil, M. Melino, J. Lee, V. Fernandez, and R. Heyrman, “Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients,” Clinical Therapeutics, vol. 32, pp. 1252–1269, 2010. View at Google Scholar
  17. D. A. Calhoun, N. A. Crikelair, J. Yen, and R. D. Glazer, “Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety,” Advances in Therapy, vol. 26, no. 11, pp. 1012–1023, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. M. Ruilope and A. Schaefer, “Efficacy of Sevikar compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: rationale and design of the SEVITENSION study,” Contemporary Clinical Trials, vol. 32, no. 5, pp. 710–716, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Bhatt, S. Singh, G. Subbaiah, B. Shah, S. Kambli, and S. Ameta, “A rapid and sensitive liquid chromatography-tandem mass spectrometry (LS-MS/MS) method for the estimation of amlodipine in human plasma,” Biomedical Chromatography, vol. 21, no. 2, pp. 169–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Vonaparti, M. Kazanis, and I. Panderi, “Development and validation of a liquid chromatographic/electrospray ionization mass spectrometric method for the determination of benazepril, benazeprilat and hydrochlorothiazide in human plasma,” Journal of Mass Spectrometry, vol. 41, no. 5, pp. 593–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. N. V. S. Ramakrishna, K. N. Vishwottam, S. Manoj, M. Koteshwara, S. Wishu, and D. P. Varma, “Sensitive liquid chromatography-tandem mass spectrometry method for quantification of hydrochlorothiazide in human plasma,” Biomedical Chromatography, vol. 19, no. 10, pp. 751–760, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Liu, J. Zhang, Y. Xu, S. Gao, and Q. Guo, “Simultaneous determination of hydrochlorothiazide and valsartan in human plasma by liquid chromatography/tandem mass spectrometry,” Analytical Letters, vol. 41, no. 8, pp. 1348–1365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. V. Ramani, P. Sengupta, and R. Mullangi, “Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study,” Biomedical Chromatography, vol. 23, no. 6, pp. 615–622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. Q. Yu, Z. Y. Hu, F. Y. Zhu et al., “HPLC-MS-MS for the simultaneous determination of atorvastatin and amlodipine in plasma of hypertensive patients,” Chromatographia, vol. 73, no. 3-4, pp. 257–262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Liu, P. Hu, N. Matsushima, X. Li, L. Li, and J. Jiang, “Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry,” Journal of Chromatography B, vol. 856, no. 1-2, pp. 190–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Ma, F. Qin, X. Sun, X. Lu, and F. Li, “Determination and pharmacokinetic study of amlodipine in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 43, no. 4, pp. 1540–1545, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Macek, J. Klíma, and P. Ptáček, “Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography,” Journal of Chromatography B, vol. 832, no. 1, pp. 169–172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Daneshtalab, R. Z. Lewanczuk, and F. Jamali, “High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method,” Journal of Chromatography B, vol. 766, no. 2, pp. 345–349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. L. González, J. A. López, R. M. Alonso, and R. M. Jiménez, “Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection,” Journal of Chromatography A, vol. 949, no. 1-2, pp. 49–60, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. H. C. Yao, M. Sun, X. Y. Yang, Z. Z. Zhang, and H. Li, “Simultaneous determination of captopril and hydrochlorothiazide by time-resolved chemiluminescence with artificial neural network calibration,” Journal of Pharmaceutical and Biomedical Analysis, vol. 1, pp. 32–38, 2011. View at Google Scholar
  31. T. Huang, Z. He, B. Yang, L. Shao, X. Zheng, and G. Duan, “Simultaneous determination of captopril and hydrochlorothiazide in human plasma by reverse-phase HPLC from linear gradient elution,” Journal of Pharmaceutical and Biomedical Analysis, vol. 41, no. 2, pp. 644–648, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Brent Miller and C. Amestoy, “A liquid chromatographic method for the determination of hydrochlorothiazide in human plasma,” Journal of Pharmaceutical and Biomedical Analysis, vol. 10, no. 7, pp. 541–545, 1992. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Niopas and A. C. Daftsios, “A validated HPLC method for the determination of hydrochlorothiazide in human plasma and its application in pharmacokinetic studies,” Journal of Liquid Chromatography and Related Technologies, vol. 25, no. 3, pp. 487–494, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Medvedovici, C. Mircioiu, V. David, and D. S. Miron, “Liquid extraction and HPLC-DAD assay of hydrochlorothiazide from plasma for a bioequivalence study at the lowest therapeutic dose,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 25, no. 2, pp. 91–96, 2000. View at Google Scholar · View at Scopus
  35. K. Richter, R. Oertel, and W. Kirch, “New sensitive method for the determination of hydrochlorothiazide in human serum by high-performance liquid chromatography with electrochemical detection,” Journal of Chromatography A, vol. 729, no. 1-2, pp. 293–296, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Francotte, A. Davatz, and P. Richert, “Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester,” Journal of Chromatography B, vol. 686, no. 1, pp. 77–83, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. ICH, Q1A Stability Testing of New Drug Substances and Products, International Conference on Harmonization, Geneva, Switzerland, 1993.
  38. Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, CDER, Rockville, Md, USA, 2001.
  39. Text on Validation of Analytical Procedures Q2A, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, London, UK, 1994.